DNA methylation: An alternative pathway to cancer

Annals of Surgery

Volumn 234, Issue 1, 2001, Pages 10-20

  Wajed, S A ^a   Laird, P W ^a   DeMeester, T R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

BASE PAIRING; CANCER; CANCER TISSUE; CARCINOGENESIS; CELL FUNCTION; DNA METHYLATION; DNA SEQUENCE; DNA STRUCTURE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; COLONIC NEOPLASMS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICROSATELLITE REPEATS; NEOPLASMS; OVARIAN NEOPLASMS; POINT MUTATION; PROMOTER REGIONS (GENETICS);

EID: 0034929515     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200107000-00003     Document Type: Review

References (99)

1. The hallmarks of cancer
2. Mutation and cancer: Statistical study of retinoblastoma
3. Cancer epigenetics comes of age
4. Genetic implications of the structure of deoxyribonucleic acid
5. DNA methylation and gene function
6. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin
7. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
8. Gene silencing. Methylation meets acetylation
9. The discovery of 5-methyl-cytosine in tuberculinic acid, the nucleic acid of the tubercle bacilus
10. The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography
11. The role of DNA methylation in cancer genetic and epigenetics
12. Methylation of the Epstein-Barr virus genome in normal lymphocytes
13. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
14. DNA methylation in early development
15. An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome
16. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development
17. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene
18. Mechanisms of X-chromosome regulation
19. DNA methylation and genomic imprinting
20. Hypomethylation distinguishes genes of some human cancers from their normal counterparts
21. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas
22. Oncogenic mechanisms mediated by DNA methylation
23. Hypomethylation of DNA from benign and malignant human colon neoplasms
24. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
25. Patterns of methylation of the c-myc gene in human colorectal cancer progression
26. CpG-rich islands and the function of DNA methylation
27. Suppression of intestinal neoplasia by DNA hypomethylation
28. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
29. A cell cycle regulator potentially involved in genesis of many tumor types
30. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
31. Rates of p16 (MTS1) mutations with 9p loss
32. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas
33. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
34. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
35. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines
36. Relaxation of imprinted genes in human cancer
37. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour
38. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype
39. Aging and DNA methylation in colorectal mucosa and cancer
40. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas
41. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
42. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors
43. Low frequency of p16/CDKN2A methylation in sporadic melanoma: Comparative approaches for methylation analysis of primary tumors
44. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing
45. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
46. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability
47. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
48. Association between CpG island methylation and microsatellite instability in colorectal cancer
49. Mechanisms of inactivation of E-cadherin in breast cancer cell lines
50. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
51. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma
52. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers
53. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
54. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
55. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure
56. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms
57. Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression
58. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells
59. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma
60. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma
61. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
62. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics
63. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
64. CpG island methylator phenotype in colorectal cancer
65. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
66. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer
67. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase over expression
68. CpG methylation is maintained in human cancer cells lacking DNMT1
69. A mammalian protein with specific demethylase activity for mCpG DNA
70. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
71. Complete and tissue-independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers
72. Hepatocarcinogenesis in rats fed methyl-deficient, amino acid-defined diets
73. Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine-treated rats
74. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men
75. Mechanisms for the involvement of DNA methylation in colon carcinogenesis
76. The pattern of spontaneous germ-line mutation: Relative rates of mutation at or near CpG dinucleotides in the factor IX gene
77. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis
78. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
79. DNA hypomethylation leads to elevated mutation rates
80. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus
81. Barrett's esophagus: Its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux
82. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
83. Association of p53 mutations with short survival in colorectal cancer
84. Free DNA in the serum of cancer patients and the effect of therapy
85. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance
86. Molecular detection of genetic alterations in the serum of colorectal cancer patients
87. Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations
88. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
89. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
90. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients
91. Hormone receptors: Their role in predicting prognosis and response to endocrine therapy
92. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer
93. Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors
94. Methylation of estrogen and progesterone receptor gene 5CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors
95. Altering gene expression with 5-azacytidine
96. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression
97. Pharmacological approach for optimization of the dose schedule of 5-Aza-2-deoxycytidine (Decitabine) for the therapy of leukemia
98. Toxicity of 5-aza-2-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
99. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer